The CEO of Maze Therapeutics' shares his perspective on FTC's scuttling of his company's licensing deal with Sanofi

Jason Coloma shares the smaller company's perspective of how a licensing deal was scuttled by the FTC and what it might mean for the broader industry. He also introduces us to Maze's approach and programs.